2 news items
Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
AQST
7 May 24
. Regarding mouth conditions, the FDA recommended administering Anaphylm after oral exposure to a known allergen and assessing PK performance thereunder
Aquestive Therapeutics Announces Pivotal Study for Anaphylmâ„¢ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting
AQST
14 Mar 24
after oral exposure to a known allergen and assessing PK performance thereunder. The Company will execute this study in the second quarter of 2024
- Prev
- 1
- Next